ACTRN12624000239561已完成1 期
A Single Ascending dose to assess the safety, tolerability and pharmacokinetics of TP-317 under fasted conditions in adult healthy volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Males and females aged 18 to 65 years, inclusive at time of signing informed consent form
- •a. Female participants of childbearing potential may participate but are required to either abstain from sexual intercourse or use two highly effective methods of
- •contraception during the study, and for at least 30 days after the last dose of study medication.
- •b. Female participants must not be pregnant or breastfeeding at Screening or during the study period, and for 30 days after the final study drug administration.
- •c. Male participants with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during the study and for at least 90 days after the last dose of study medication.
- •d. Sperm donation is prohibited during the study for at least 90 days and ova donation is prohibited during the study for at least 30 days after the last dose of study medication
- •2. Must meet the following laboratory criteria during Screening
- •a. Acceptable renal function defined as calculated creatinine clearance 90 mL/min/1.73 m2 or greater by Cockcroft-Gault:
- •b. Neutrophil count within the normal reference range
- •c. Platelet count > 100,000 µl
- •d. Eosinophil count within normal reference range
- •e. basophil count within normal reference range
- •f. Hemoglobin > normal reference range
- •g. PT within normal reference range
- •h. PTT within normal reference range
- •i. Serum creatinine within the normal reference range
- •3. Body Mass Index of 18 – 35 kg/m2 inclusive
- •4. Must agree to abstain from tobacco and/or cannabis use from Screening visit through safety follow-up visit.
- •5. Able to swallow numerous pills (i.e., study medication) at one time or in quick succession.
- •6. Willing and capable of giving written informed consent, which includes being able to comply with all aspects of the study treatment and testing schedule.
- •7. Will not participate in another interventional study while in this clinical study.
排除标准
- •1. History of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years prior to screening or the participant tests positive at the Screening or upon admission to the CRU for alcohol
- •2. History of substance abuse or dependency in the last 12 months, or a history of recreational intravenous drug use over the last 5 years (by self-declaration), or a positive toxicology screening panel (urine test including qualitative identification of amphetamines, barbiturates, benzodiazepines, THC, cocaine, and opiates) or positive testing identified by Phase 1-unit standard drug screening panel at Screening Visit or upon admission to study unit
- •3. Chronic use of cannabis and/or tobacco defined as daily use for greater than 3 months
- •4. Has greater than 6 months of chronic back pain, Grade 2 or greater, requiring chronic analgesic use, defined as requiring analgesics most days.
- •5. Any abnormal laboratory test results assessed as clinically significant by the Investigator.
- •6. Has alkaline phosphatase (ALP), aspartate transaminase (AST) and/or alanine transaminase (ALT) levels or total bilirubin >1.5 × the upper limit of normal (ULN),
- •Participants with a total bilirubin >2 x ULN that have a documented diagnosis of Gilbert’s syndrome may be enrolled
- •7. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in
- •situ such as cervical or breast carcinoma that has been excised or resected completely and is without evidence of local recurrence or metastasis.
- •8. Has any medical condition (acute or chronic illness) or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant’s
- •ability to participate in this study such as but not limited to: Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease. Presence
- •or history of any significant hemorrhage, thromboembolic diseases or diatheses such as hypercoagulability, platelet disorder, or erythrocytosis.
- •9. Any surgical procedure (except for procedures determined by the investigator to be minor) within 4 weeks prior to the Screening Visit
- •10. Use of concomitant medication (including over the counter medication, health supplements, multivitamins and vitamin C, vitamin and omega-3 supplements, and herbal remedies such as St. John’s Wort extract) must be stopped at least 14 days prior to the first dose and not restarted until Day 7
- •11. Unable to stop use of proton pump inhibitors, H2 -receptor antagonists and antacids for 14 days prior to study drug administration through 7 days post study drug administration
- •12. Received a live vaccine within 4 weeks prior to Screening visit.
- •13. Know hypersensitivity to the study drug or it’s excipients thereof, or drug or other allergy that, in the opinion of the Investigator contraindicates participation in the study.
- •14. Intake of more than 6 cups of coffee or tea or equivalent of caffeinated beverages per day for > 3 months.
- •15. Positive test for hepatitis B virus (HBsAg), hepatitis C virus (HCV) antibodies, HIV1 or HIV2 at Screening Visit (participants testing positive for Hep B that have been treated be enrolled at investigator discretion)
- •16. Cannot have donated blood (quantified by 10% of pa
研究者
相似试验
已完成
不适用
Ascending single dose study of the safety, tolerability, and pharmacokinetics of PRM-151 administered to healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF)NL-OMON33156Centre for Human Drug Research32
已完成
不适用
ASCENDING SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACO-DYNAMICS OF SRA-444 ADMINISTERED ORALLY TO HEALTHY ADULT SUBJECTSneurological disorder10011305DementiaNL-OMON30387Wyeth64
已完成
不适用
A single ascending dose study to assess the safety, tolerability and pharmacokinetics of RO5428029 in healthy male subjectsHCVHepatitis C Virus infectioninfection of the liver10047438NL-OMON34361Roche Nederland B.V.60
已完成
1 期
A Single Dose Study to investigate the safety of ACH-0145228 in Healthy Volunteers.ACTRN12617001521314Achillion Pharmaceuticals, Inc.28
招募中
1 期
A Phase I, Single Ascending Dose, Safety and Pharmacokinetic Study of PN0621 in Healthy VolunteersInflammatory dieseases, Healthy VolunteersInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12607000275460Peptech Limited30